Abadisept: A Trial and Error Candidate in Chronic GVHD

There was a decrease in expression of PD-1 on circulating CD4 positive T cells after abadisept therapy. However, there were no significant differences in pre or post-treatment levels of these cytokines and responders as compared to non-responders. There is an urgent need for a biomarker to predict response to different classes of agents used to treat chronic GVHD. Such markers could enable biology-driven treatment geared toward preventing the progression of the disease towards non-reversible changes.